Last updated on March 2019

A Study of ABBV-927 and ABBV-181 an Immunotherapy in Subjects With Advanced Solid Tumors


Brief description of study

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.

Clinical Study Identifier: NCT02988960

Find a site near you

Start Over

Austin Health /ID# 171189

Melbourne, Australia
8.16miles
  Connect »